TABLE 2.
Baseline characteristics of the matched cohort
| STN subgroup | GPi | P‐value | ||
|---|---|---|---|---|
| N | 21 | 21 | ||
| Gender (%) | Male | 10 (47.6) | 9 (42.9) | 1.000 |
| Female | 11 (52.4) | 12 (57.1) | ||
| Age at surgery | 68.83 (5.25) | 70.11 (6.77) | 0.497 | |
| Disease duration (yr) | 13.60 (3.86) | 14.51 (4.75) | 0.504 | |
| Time from surgery to assessment (weeks) | 59.35 (16.77) | 61.72 (21.56) | 0.693 | |
| PDQ‐39 SI | 34.19 (11.80) | 34.52 (10.25) | 0.923 | |
| LEDD | 1096.67 (456.85) | 1149.05 (483.28) | 0.720 | |
| MDS‐UPDRS‐III (off medication) | 42.90 (11.16) | 41.76 (12.95) | 0.761 | |
| MDS‐UPDRS‐III (% improvement) | 56.19 (10.76) | 54.67 (10.21) | 0.640 | |
| Schwab and England | 58.90 (17.38) | 62.86 (13.09) | 0.410 | |
| MMSE | 27.86 (1.20) | 27.38 (1.72) | 0.303 | |
| Hamilton | 8.24 (7.78) | 6.38 (4.68) | 0.354 | |
| Starkstein | 14.38 (5.71) | 12.90 (5.26) | 0.389 | |
| Pain | 4.77 (3.34) | 4.53 (2.89) | 0.802 | |
| Marconi | 7.76 (5.73) | 9.00 (5.07) | 0.463 | |
| Insomnia | 1.52 (1.50) | 1.76 (1.30) | 0.586 | |
| Postural stability | 0.81 (0.60) | 1.14 (0.96) | 0.186 | |
| Stimulator type (%) | Medtronic | 15 (71.4) | 16 (76.2) | 1.000 |
| Boston | 6 (28.6) | 5 (23.8) | ||
Note: Continuous variables are summarized by mean and standard deviation (in parentheses), whereas the categorical variables are listed in counts and percentage (in parentheses).
Abbreviations: STN, subthalamic nucleus; GPI, globus pallidus internus; PDQ‐39 SI, Parkinson's Disease Questionnaire Summary Index; LEDD, levodopa equivalent daily dose; MDS‐UPDRS‐III, Movement Disorder Society Unified Parkinson's Disease Rating Scale, Part III; MMSE, Mini‐Mental State Examination.